Q-omics provides the consensus-scored ALOXE3 profile across patient tissues and cancer cell-line models. ALOXE3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ALOXE3 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, ALOXE3 RNA expression shows 14,221 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, LUAD, and GBM as cancer lineages where ALOXE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALOXE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALOXE3 survival associations across molecular data types. ALOXE3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALOXE3 RNA expression–survival associations across cancer types. High ALOXE3 expression shows unfavorable associations in COAD, KIRP, KIRC, UCEC, LUAD and SCLC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ALOXE3 RNA expression.
This table summarizes ALOXE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ALOXE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALOXE3 shows higher tumor expression in LUAD, COAD, LUSC, BRCA, KIRP and THCA. The LUAD box plot shows higher ALOXE3 RNA expression in tumor versus normal tissue (log2 FC = +0.457, t-test p < 0.001).
This table shows molecular features associated with ALOXE3 in patient tissues and cancer cell lines. In patient samples, ALOXE3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALOXE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
